Summary
In the REAL classification the diffuse large B-cell non-Hodgkin lymphomas (NHL) are grouped together, because subclassifications are considered to lack both reproducibility and clinical significance. Others, however, claim that patients with an immunoblastic NHL have a worse prognosis than patients with other types of diffuse large B-cell NHL. Therefore, we investigated the prognostic and clinical significance of histological subclassification of diffuse large B-cell NHL in a uniformly treated series of patients. For this retrospective study, all patients diagnosed as having an immunoblastic (IB) B-cell NHL by the Lymphoma Review Panel of the Comprehensive Cancer Center Amsterdam (CCCA) between 1984 and 1994, and treated according to the guidelines of the CCCA, were analysed. Patients with a centroblastic polymorphic subtype (CB-Poly) or centroblastic (CB) NHL by the Lymphoma Review Panel who were treated in the Netherlands Cancer Institute during the same period according to CCCA guidelines were used as reference groups. All patients’ records were reviewed. Clinical parameters at presentation, kind of therapy and clinical outcome were recorded. All available histological slides were separately reviewed by two haemato-pathologists. One hundred and seventy-seven patients were included in the study: 36 patients (20.3%) with an IB NHL, 69 patients (39%) with a CB-Poly NHL and 72 patients (40.7%) with a CB NHL. The patients with an IB NHL tended to be older and presented more often with stage I or II and one extranodal site than patients with a CB and CB-Poly NHL. None of the subtypes showed a clear preference for localization in a particular site. The patients with IB or CB-Poly NHL showed a significantly worse prognosis than patients with CB NHL, with a 5-year overall survival for patients with CB NHL of 56.3% and for patients with IB or CB-Poly NHL 39.1% and 41.6% respectively. The 5-year disease free survival was 53.2% for the patients with CB, 32% for the patients with CB-Poly and 26.9% for the patients with IB NHL. A multivariate analysis showed that histological subtyping was of prognostic significance independent of the International Prognostic Index. This finding merits further exploration in prospective studies in order to judge the value of subclassification of large B-cell NHL as a guideline in therapy choice.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Berard, C. W. & Hutchison, R. E. (1997). The problem of classifying lymphomas: an orderly prescription for progress. Ann Oncol 8(suppl 2): S3–S9.
Bos, G. J. M., van Putten, W. L. J., vd Holt, B., vd Bent, M., Verdonck, L. F. & Hagenbeek A., on behalf of the Dutch HOVON group (1998). For which patients with aggressive non-Hodgkin’s lymphoma is prophylaxis for central nervous system disease mandatory?. Ann Oncol 9: 191–194.
Canellos, G. P. (1997). CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. J Clin Oncol 15: 1713–1716.
Carbone, A., Gaidano, G., Gloghini, A., Larocca, L. M., Capello, D., Canzonieri, V., Antinori, A., Tirelli, U., Falini, B. & Dalla-Favera, R. (1998). Differential expression of BCL-6, CD138/Syndecan-1, and Epstein-Barr Virus-Encoded Latent Membrane Protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas. Blood 91: 747–755.
Dumont, J., Charpy-Validire, P., Raphael, M., Ulliez, M., Le Doussal, V., Barge, J. & Mosseri, V. (1992). Lymphomas à grandes cellules: influence des groupes histologiques sur le pronostic. Etude de 210 cas soumis aux mêmes protocoles thérapeutiques. Arch Anat Cytol Path 40: 110–114.
Engelhard, M., Brittinger, G., Huhn, D., Gerharts, H. H., Meusers, P., Siegert, W., Thiel, E., Wilmanns, W., Aydemir, U., Bierwolf, S., Griesser, H., Tiemann, M. & Lennert, K. (1997). Subclassification of diffuse large B-cell lymphoma according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 89: 2291–2297.
Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. C., Cleary, M. L., Delsol, G., de Wolf-Peeters, C., Falini, B., Gatter, K. C., Grogan, T. M., Isaacson, P. G., Knowles, D. M., Mason, D. Y., Muller-Hermelink, H. K., Pileri, S. A., Piris, M. A., Ralfkiaer & Warnke, R. A. (1994). Revised European–American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361–1392.
van Heerde, P., Meijer, CJLM, Noorduyn, L. A. & van der Valk, P. (1996). An Atlas and Textbook of Malignant Lymphomas. Cytology, Histopathology and Immunochemistry pp 25–62. Harvey Miller Publishers, Manson Publishing: London
Hvizdala, E. V., Berard, C., Callihan, T., Falletta, J., Sabio, H., Shuster, J. J., Sullivan, M. & Wharam, M. D. (1991). Nonlymphoblastic lymphoma in children – histology and stage-related response to therapy: a pediatric oncology group study. J Clin Oncol 9: 1189–1195.
Jaffe, E. S., Harris, N. L., Chan, J. K. C., Stein, H. & Vardiman, J. W. (1997). Society for Hematopathology Program. Proposed World Health Organization Classification of neoplastic diseases of hematopoietic and lymphoid tissues. Am J Surg Pathol 21: 114–121.
Koza, I., Mardiak, J., Bohunicky, L., Svancárová, L., Fuchsberger, P., Gyárfás, J., Horák, I., Spánik, S., Sufliarsky, J., Thalmeinerová, Z. & Cerny, V. (1992). Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas – long-term observation. Neoplasma 39: 43–47.
Kwak, L., Wilson, M., Weiss, L. M., Horning, S. J., Warnke, R. A. & Dorfman, R. F. (1991). Clinical significance of morphologic subdivision in diffuse large cell lymphoma. Cancer 68: 1988–1993.
Lennert, K. & Feller, A. C. (1990). Histopathologie der Non-Hodgkin-Lymphome (nach der aktualisierten Kiel-Klassification), 2nd ed., pp 100–122. Springer: Berlin
Murphy, S. B., Fairclough, D. L., Hutchison, R. E. & Berard, C. W. (1989). Non-Hodgkin’s lymphoma of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 7: 186–193.
Rodriquez, J. M. & Khan, A. A. (1995). Combined chemotherapy and radiotherapy in diffuse large cell immunoblastic lymphoma: a phase II study of CHOP/bleomycin/methotrexate alternating with ifosfamide/methotrexate/etoposide. Clin Oncol 7: 113–116.
Rosenberg, S. A., Berard, C. W., Brown, B. W., Burke, J., Dorman, R. F., Glatstein, E., Hoppe, R. T. & Simon R., Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982). National Cancer Institute sponsored study of classifications of non-Hodgkin’s Lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49: 2112–2135.
Shipp, M. A., Harrington, D. P., Anderson, J. R., Armitage, J. O., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G. P., Coiffier, B., Connors, J. M., Cowan, R. A., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R. I., Gisselbrecht, C., Horning, S. J., Lepage, E., Lister, T. A., Meerwaldt, J. H., Monterrat, E., Nissen, N. I., Oken, M. M., Peterson, B. A., Tondini, C., Velasquez, W. A. & Yeap, B. Y. (1993). A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329: 987–994.
Simon, R., Durrleman, S., Hoppe, R. T., Bonadonna, G., Bloomfield, C. D., Rudders, R. A., Cheson, B. & Berard, C. W. (1988). The non-Hodgkin Lymphoma Classification Project. Long term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med 109: 939–945.
Stein, H. & Dallenbach, F. (1992). Diffuse large cell lymphomas of B and T cell type. In Neoplastic Hematopathology, Knowles DM. (ed) pp 675–714. Williams & Wilkins: Baltimore
Wijdenes, J., Vooijs, W. C., Clément, C., Post, J., Morard, F., Vita, N., Laurent, P., Sun, R-X, Klein, B. & Dore, J-M (1996). A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94: 318–323.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Baars, J., Jong, D., Willemse, E. et al. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification. Br J Cancer 79, 1770–1776 (1999). https://doi.org/10.1038/sj.bjc.6690282
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690282